Background: There is an ongoing search for new therapeutic targets in invasive non-resectable thymic tumours because of the low response rates in current chemotherapeutic treatment modalities. In this study, the possibility that platelet-derived growth factor receptor A (PDGFRA) and/ or PDGFRB may represent potential therapeutic targets in epithelial tumours of the thymus was investigated.
Patients And Methods: Tissue samples were obtained by thymectomy from 36 different patients with epithelial tumours of the thymus (26 thymomas types A, AB, B1-3 and 10 thymic carcinomas). Normal thymi from three young children were used as controls. The PDGFRA and PDGFRB protein expressions as well as the mutational statuses of exons 12, 14 and 18 of the PDGFRA gene were analyzed.
Results: All the subtypes of thymomas and the thymic carcinomas showed staining for PDGFRA, but no mutations in the known mutational hotspots were identified. Only about one third of the tumours stained for PDGFRB. PDGFRA and PDGFRB protein staining were slightly positively correlated.
Conclusion: PDGFRA may represent a potential therapeutic target in thymic tumours.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Multimodal management and complete resection of invasive Type B3 thymoma with vascular reconstruction: a case report.
J Cardiothorac Surg
January 2025
Department of Thoracic Surgery, Guy's and St Thomas' NHS Foundation Trust, London, England.
Introduction: Thymomas and thymic carcinomas are rare anterior mediastinal tumours, accounting for 0.2-1.5% of all cancers.
View Article and Find Full Text PDFCausal Relationship Between Physical Activity and Thymic Tumors Mediated by Circulating Cytokines: A Mendelian Randomization Mediation Analysis.
Int J Mol Sci
December 2024
Department of Sports Science, Hanyang University ERICA, Ansan 15588, Republic of Korea.
Physical activity reduces chronic disease risk and enhances immune function, but its causal relationship with thymic tumors-rare neoplasms of the anterior mediastinum-remains unclear. This study investigated whether physical activity reduces thymic tumor risk and whether circulating cytokines mediate this effect. We performed a two-sample Mendelian randomization (MR) analysis using genetic variants as instrumental variables for physical activity and cytokines.
View Article and Find Full Text PDFPrenatal diagnosis of mucopolysaccharidosis type I on hepatosplenomegaly and coarse features: a case-report.
BMC Pregnancy Childbirth
January 2025
Department of Clinical Genetics, Rennes University Hospital, Rennes, France.
Background: Mucopolysaccharidosis type I (MPS I - IDUA gene) is a rare autosomal recessive lysosomal storage disorder. Clinical symptoms, including visceral overload, are progressive and typically begin postnatally. Descriptions of hepatosplenomegaly associated with lysosomal pathology are uncommon during the prenatal period.
View Article and Find Full Text PDFEctopic ACTH syndrome caused by thymic neuroendocrine tumour - stages of treatment.
Endokrynol Pol
December 2024
Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland.
Not required for Clinical Vignette.
View Article and Find Full Text PDF[Intrathyroid thymic carcinoma: report of a case].
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
January 2025
Intrathyroid thymic carcinoma（ITTC） is a rare thyroid tumor that lacks typical clinical manifestations and imaging features, making preoperative diagnosis challenging.The primary treatment for ITTC is radical surgery; however, the effectiveness of adjuvant radiotherapy and chemotherapy post-surgery is not well-established. This paper presents a case of ITTC , analyzing the clinical data and correlating it with the literature to explore the clinical manifestations, diagnostic approach, treatment, and prognosis of ITTC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!